HER-2阴性晚期乳腺癌最新ASCO推荐 According to ASCO, about 75% of advanced breast cancers areHER2-negative. Although targeted therapies are beginning to emerge, the development of drugs forHER2-negative disease has lagged behind that forHER2-positive disease, which has already produced targeted agents ...
chemotherapy and radiation are the most important treatments for Her-2 negative breast cancer due to poor targeted therapy.Neoadjuvant chemotherapy has many advantages, for example, it can reduce tumor stage,to achieve surgical operation,maintain breast and armpit, and provide sensitive...
HER-2 negative breast cancerHormonal- resistanceTargeted cancer therapyTriple negative breast cancerAntibody drug conjugates (ADCs) comprise a rapidly growing class of targeted drugs that selectively deliver a cytotoxic agent to cancer cells, reducing the side effects associated with conventional chemotherapy...
According to ASCO, about 75% of advanced breast cancers are HER2-negative. Although targeted therapies are beginning to emerge, the development of drugs for HER2-negative disease has lagged behind that for HER2-positive disease, which has already produced targeted agents such astrastuzumab(Herceptin)...
(HER2-negative) breast cancer (n = 113; objective response rate [ORR], 30.1%; median progression-free survival [mPFS], 7.4 months), triple-negative breast cancer (n = 53; ORR, 22.6%; mPFS, 5.5 months), and HER2-positive breast cancer (n = 14; ORR, 42.9%; mPFS, 11.0 months). ...
New molecular classification is one of the cornerstones of current and future progress in research and patient care for breast carcinoma. For the larger hormone-receptor positive and Her-2 negative subgroup, which concerns 75% of the patients, endocrine therapy and chemotherapy may be considered. Lo...
01-关于her-2阴性胃癌治疗 根据现行国际各大指南标准[5]，铂类联合氟尿嘧啶类药物为基础的全身化疗是晚期 HER-2 阴性胃癌的一线标准治疗，且化疗通常持续至直至疾病进展。然而铂类药物的累积毒性通常会使患者的身体状态进一步恶化。临床中，患者持续化疗至出现无法耐受的毒性后，通常使用氟尿嘧啶类药物单药治疗。此外，...
HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers[J]. Cancer Sci, 2017, 108(4):671-677. [42] SI P, XU Y, OUYANG T, et al. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer[J]. Cancer Biomark, ...
Background: HER-2/neu is a proto-oncogene that is amplified/overexpressed in 15 to 30% of invasive breast cancers. The purpose of this study was to determine if any relationship exist between HER-2/neu protein overexpression and estrogen receptor (ER), progesterone receptor (PR), grade, ...
We compared the results from 2laboratories for HER-2/neu determined by IHC on paraffin sections of the same 100 consecutive invasive breast cancers. Both laboratories used the same primary antibody; however, different methods for heat-induced epitope retrieval (microwave or steam) and immunostaining ...